CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Lekakis on Real-World Data With CAR T-Cell Therapy in Lymphoma

April 2nd 2019

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses real-world data with CAR T-cell therapy from the 2018 ASH Annual Meeting.

Dr. Adusumilli on Autologous Mesothelin-Targeted CAR T Cells in Advanced Solid Tumors

April 1st 2019

Prasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discussed the results of a phase I study exploring mesothelin-targeted CAR T-cell therapy in patients with advanced solid tumors during the 2019 AACR Annual Meeting.

CAR T Cells Targeting Mesothelin Show Strong Early Signal in Advanced Solid Cancers

April 1st 2019

CAR T cells targeting mesothelin-expressing tumors demonstrated safety and efficacy in a preliminary clinical evaluation in patients with malignant pleural disease.

CAR T-Cell Therapy and Lymphodepletion Shows Early Efficacy, Tolerability in Advanced Sarcoma

April 1st 2019

The administration of HER2-directed CAR T-cell therapy and lymphodepletion chemotherapy demonstrated antitumor activity and was found to be safe in pediatric and adult patients with advanced HER2-positive sarcoma.

Novel CAR Therapy Shows Promising Early Signals in Pancreatic Cancer

March 31st 2019

Although CAR T-cell therapy has not yet proved effective against solid tumors, a novel CAR that targets mesothelin proteins expressed in pancreatic cancer is showing early signs of activity.

Sequential CD19- and CD22-Directed CAR T-Cell Therapy Improves Long-Term Remission in Relapsed/Refractory B-ALL

March 28th 2019

Sequential administration of CAR T-cell therapy targeting both the CD19 and CD22 antigens demonstrated high complete remission rates and improved long-term survival in patients with relapsed/refractory B-cell acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplant.

CAR T Cells Bring Promise to Patients With ALL, DLBCL With Poor Prognosis

March 26th 2019

Lazaros J. Lekakis, MD, discusses the promise of CAR T cells and some unanswered questions with this rapidly emerging therapy.

Nimer Highlights Treatment Trends Across Hematologic Malignancies

March 25th 2019

Stephen D. Nimer, MD, sheds light on new strategies and trends in the treatment of patients with hematologic malignancies.

Dr. Nimer on CAR T-Cell Therapy in Hematologic Malignancies

March 19th 2019

Stephen D. Nimer, MD, professor of medicine, director, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Dr. Lekakis on Current Research With CAR T-Cell Therapy

March 15th 2019

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Dr. Raje on bb21217 in Multiple Myeloma

March 15th 2019

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses preliminary data on bb21217 in multiple myeloma.

What's Keeping CAR T-Cell Therapies From the Outpatient Setting?

March 13th 2019

Although these therapies were initially conceived of and developed as inpatient therapies, interest is growing in extending chimeric antigen receptor T-cell therapies to the outpatient setting.

Dr. Kambhampati on the Potential of CAR T-Cell Therapy in CLL

March 8th 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL).

Dr. Park Discusses Use of CAR T Cells in ALL

March 5th 2019

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the use of CAR T cells in the treatment of patients with acute lymphoblastic leukemia.

CD30 CAR T Cells Active in Hodgkin Lymphoma

February 25th 2019

Chimeric antigen receptor T cells targeting CD30 proved to be safe and active in relapsed/refractory Hodgkin lymphoma.

Dr. Maziarz on Sustained Responses With Tisagenlecleucel in DLBCL

February 20th 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses sustained responses with tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.

CMS Proposes Coverage With Evidence Development for CAR T-Cell Therapy for Cancers

February 19th 2019

The Centers for Medicare & Medicaid Services has proposed to cover chimeric antigen receptor T-cell therapies approved by the FDA, under “Coverage with Evidence Development."

Ibrutinib/JCAR014 Combo Shows Potential in Relapsed/Refractory CLL

February 13th 2019

Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.

Dr. Ghobadi on the Safety of CAR T-Cell Therapy in Hematologic Malignancies

February 13th 2019

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.

Following Progression on CAR T-Cell Therapy, B-Cell Lymphoma Treatment Options Needed

February 12th 2019

Victor A. Chow, MD, discusses the next steps in understanding how to treat patients with large B-cell lymphomas who progress after chimeric antigen receptor T-cell therapy.